What can patients tell us in Sjögren's syndrome?

Rheumatol Immunol Res. 2024 Mar 31;5(1):34-41. doi: 10.1515/rir-2024-0004. eCollection 2024 Mar.

Abstract

In Sjögren's Syndrome (SS), clinical heterogeneity and discordance between disease activity measures and patient experience are key obstacles to effective therapeutic development. Patient reported outcome measures (PROMs) are useful tools for understanding the unmet needs from the patients' perspective and therefore they are key for the development of patient centric healthcare systems. Initial concern about the subjectivity of PROMs has given way to methodological rigour and clear guidance for the development of PROMs. To date, several studies of patient stratification using PROMs have identified similar symptom-based subgroups. There is evidence to suggest that these subgroups may represent different disease endotypes with differing responses to therapeutic interventions. Stratified medicine approaches, alongside sensitive outcome measures, have the potential to improve our understanding of SS pathobiology and therapeutic development. The inclusion of PROMs is important for the success of such approaches. In this review we discuss the opportunities of using PROMs in understanding the pathogenesis of and therapeutic development for SS.

Keywords: Sjögren’s; composite endpoints; electronic patient-reported outcomes; endotypes; heterogeneity; newcastle Sjögren’s stratification tool; patient-reported outcomes; stratified medicine.

Publication types

  • Review

Grants and funding

This work was supported in part by FOREUM, NECESSITY, NIHR Biomedical Research Centre at Newcastle University and the Newcastle upon Tyne Hospitals NHS Trust.